There are roughly 80,000 newly diagnosed bladder cancer cases each year in China and 70-80% are early-stage cancers, otherwise known as non-muscle invasive bladder cancer (NMIBC). The current standard care for high-risk patients who failed intravesical therapies is surgical removal of the bladder, which drastically lowers the patient’s quality of life.
Now, Shanghai-based Asieris Pharma is developing an old antibiotic – a methionine aminopeptidase II (MetAP2) inhibitor – as
China Unbound: Fourth In A Series
China has seen explosive growth in developing new drugs ranging from antibodies to cell therapies, hence the first report from a new series covering emerging biotechs in China. They range from anti-cancer developers to respiratory specialty firms, from Shanghai to Zhongshan – several made-in-China biopharma innovators that largely have been flying under the radar.
See the first three articles in this series here: Hepalink-Backed HighTide Bets On NASH For Global Markets,
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?